Iovance Biotherapeutics logo

Iovance BiotherapeuticsNASDAQ: IOVA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 October 2010

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$3.41 B
-31%vs. 3y high
86%vs. sector
-vs. 3y high
-vs. sector
-47%vs. 3y high
80%vs. sector
104.10
-98%vs. 3y high
94%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:58:22 GMT
$11.24+$0.74(+7.05%)

Dividend

No data over the past 3 years
$31.11 M$53.81 M
$31.11 M-$97.10 M

Analysts recommendations

Institutional Ownership

IOVA Latest News

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
globenewswire.com31 October 2024 Sentiment: POSITIVE

SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024.

Why Iovance Biotherapeutics Stock Triumphed on Thursday
fool.com24 October 2024 Sentiment: POSITIVE

With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.

Is Iovance Biotherapeutics Stock a Buy?
fool.com04 October 2024 Sentiment: POSITIVE

The biotech is making important breakthroughs, but is that enough?

Iovance Biotherapeutics: Moving To The Next Phase
seekingalpha.com03 October 2024 Sentiment: POSITIVE

Iovance Biotherapeutics' Amtagvi has gained rapid market traction post-FDA approval, with strong Q3 performance and promising revenue projections for 2024 and beyond. The company's growth prospects are bolstered by potential regulatory approvals in international markets and ongoing trials in other cancer types, including NSCLC. Despite the positive outlook, risks include market penetration challenges, regulatory hurdles, competition, and financial sustainability concerns due to ongoing cash burn.

3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
fool.com26 September 2024 Sentiment: POSITIVE

Iovance Biotherapeutics is laying the groundwork to start realizing lots of revenue. It also has a lot of work in progress to increase the number of patients it can help.

3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
fool.com16 September 2024 Sentiment: POSITIVE

Iovance Biotherapeutics will take some time to become profitable. It will probably see its medicine approved in more places before that happens.

This Is the Biggest Risk With Iovance Biotherapeutics Stock
fool.com06 September 2024 Sentiment: POSITIVE

Iovance Biotherapeutics obtained accelerated approval for its cell therapy, Amtagvi, earlier this year. The company has begun rolling it out, and it presents a big opportunity for the business.

Iovance Biotherapeutics to Present at Upcoming Conferences
globenewswire.com03 September 2024 Sentiment: POSITIVE

SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:

Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
fool.com27 August 2024 Sentiment: POSITIVE

The Food and Drug Administration approved Iovance Biotherapeutics' first therapy, Amtagvi, in February. Amtagvi is a complicated treatment made from immune cells found in tumor biopsies.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com16 August 2024 Sentiment: POSITIVE

SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of 289,710 shares of Iovance's common stock to twenty-four new, non-executive employees.

What type of business is Iovance Biotherapeutics?

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing products for cancer immunotherapy using the patient's own immune system to destroy cancer cells. The company utilizes its own manufacturing process for tumor therapy, which has reduced manufacturing time from 5-6 weeks to 22 days. In addition, Iovance Biotherapeutics is conducting a number of trials for the treatment of metastatic melanoma, cervical cancer, head and neck cancer, lung cancer, and other forms of cancer. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

What sector is Iovance Biotherapeutics in?

Iovance Biotherapeutics is in the Healthcare sector

What industry is Iovance Biotherapeutics in?

Iovance Biotherapeutics is in the Biotechnology industry

What country is Iovance Biotherapeutics from?

Iovance Biotherapeutics is headquartered in United States

When did Iovance Biotherapeutics go public?

Iovance Biotherapeutics initial public offering (IPO) was on 15 October 2010

What is Iovance Biotherapeutics website?

https://www.iovance.com

Is Iovance Biotherapeutics in the S&P 500?

No, Iovance Biotherapeutics is not included in the S&P 500 index

Is Iovance Biotherapeutics in the NASDAQ 100?

No, Iovance Biotherapeutics is not included in the NASDAQ 100 index

Is Iovance Biotherapeutics in the Dow Jones?

No, Iovance Biotherapeutics is not included in the Dow Jones index

When was Iovance Biotherapeutics the previous earnings report?

No data

When does Iovance Biotherapeutics earnings report?

The next expected earnings date for Iovance Biotherapeutics is 07 November 2024